GSK posts encouraging data for bowel cancer treatment Jemperli
(Alliance News) - GSK PLC on Monday reported encouraging trial data for its cancer treatment Jemperli, also known as dostarlimab. Read More
| Price | 1,910.50p on 15-07-2026 at 12:59:29 |
|---|---|
| Change | -10.00p -0.52% |
| Buy | 1,911.50p |
| Sell | 1,910.50p |
| Last Trade: | Buy 186.00 at 1,911.0501p |
| Day's Volume: | 1,175,865 |
| Last Close: | 1,920.50p |
| Open: | 1,920.50p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,908.00p - 1,922.00p |
| 52wk Range: | 1,315.00p - 2,282.00p |
| Market Capitalisation: | £76.53b |
| VWAP: | 1,914.60169p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 186 | 1,911.0501p | Ordinary |
13:59:27 - 15-Jul-26 |
| Unknown* | 1 | 1,911.00p | SI Trade |
13:58:41 - 15-Jul-26 |
| Sell* | 75 | 1,910.50p | Automatic Execution |
13:58:20 - 15-Jul-26 |
| Buy* | 89 | 1,910.00p | Automatic Execution |
13:58:09 - 15-Jul-26 |
| Buy* | 87 | 1,910.00p | Automatic Execution |
13:58:09 - 15-Jul-26 |
| Sell* | 12 | 1,909.50p | Automatic Execution |
13:57:14 - 15-Jul-26 |
| Unknown* | 0 | 1,910.00p | OTC Trade |
13:57:08 - 15-Jul-26 |
| Buy* | 28 | 1,909.50p | Automatic Execution |
13:57:08 - 15-Jul-26 |
| Sell* | 2 | 1,909.50p | Automatic Execution |
13:57:06 - 15-Jul-26 |
| Sell* | 414 | 1,909.50p | Automatic Execution |
13:57:06 - 15-Jul-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Jul 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 13th Jul 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 13th Jul 2026 7:00 am | RNS | Positive Jemperli data in dMMR/MSI-H rectal cancer |
| 10th Jul 2026 11:58 am | RNS | Hansoh positive Phase III results for Riz-Rez |
| 9th Jul 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 9th Jul 2026 10:00 am | RNS | Directorate change |
| 1st Jul 2026 3:00 pm | RNS | Total Voting Rights |
| 29th Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 29th Jun 2026 3:00 pm | RNS | Holding(s) in Company |
| 26th Jun 2026 3:00 pm | RNS | Holding(s) in Company |